Orlando, FL-Using serum testosterone levels rather than labelguidelines to re-dose patients on luteinizing hormone-releasing hormone(LHRH) agonist depot therapy can substantially reduce treatment costs andimprove a patient's quality of life, according to researchers at Case WesternReserve University, Cleveland.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.